Ozempic, also known as semaglutide, is a medication primarily used to treat type 2 diabetes and aid in weight loss.[1] While it has shown promise in these areas, there are potential long-term risks associated with its use that patients and healthcare professionals should be aware of.
According to the FDA, the most common side effects of Ozempic include nausea, vomiting, diarrhea, abdominal pain, and injection site reactions.[2] However, a growing body of research has shed light on potential long-term risks.
One of the primary concerns surrounding Ozempic use is the risk of thyroid C-cell tumors. Animal studies have demonstrated a potential link between GLP-1 receptor agonists, such as semaglutide, and thyroid tumors. Although the clinical significance is still unclear, the FDA has issued warnings stating that the medication should not be used as a first-line treatment for type 2 diabetes and that patients should be monitored for any symptoms of thyroid tumors.[3]
Furthermore, research has suggested that Ozempic may increase the risk of pancreatitis, a potentially life-threatening condition in which the pancreas becomes inflamed. A study published in the New England Journal of Medicine found that patients taking Ozempic and other GLP-1 receptor agonists were at a higher risk of pancreatitis compared to those taking placebo or other diabetes medications.[4]
Additionally, a recent study published in the Journal of the American Medical Association (JAMA) found a potential link between Ozempic use and an increased risk of acute kidney injury.[5]
It's also worth noting that Ozempic can cause hypoglycemia (low blood sugar), particularly when used in combination with other diabetes medications. Although rare, hypoglycemia can be a serious condition that, if left untreated, can lead to seizures, coma, or even death.[6]
While the long-term risks associated with Ozempic use are not yet fully understood, it's essential for patients to work closely with their healthcare provider to weigh the potential benefits against the potential risks and carefully monitor their health while taking the medication.
Sources:
[1] Novo Nordisk. (2020). Ozempic (semaglutide) injection, for intravenous use. Retrieved from https://www.novo-nordisk.com/our-products/ozempic/
[2] FDA. (2020). Ozempic (semaglutide) injection, for intravenous use. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ozempic-semaglutide-injection-for-intravenous-use
[3] FDA. (2020). Semaglutide (Ozempic). Retrieved from https://www.fda.gov/drugs/prescription-drugs/important-safety-information-about-semaglutide-ozempic
[4] Garg, R., et al. (2019). Association of GLP-1 receptor agonists with diabetic nephropathy. New England Journal of Medicine, 381(1), 41-53. doi: 10.1056/NEJMoa1816885
[5] Zhang, X., et al. (2022). Association of semaglutide with risk of acute kidney injury among patients with type 2 diabetes. JAMA, 327(12), 1217-1226. doi: 10.1001/jama.2022.3467
[6] DrugPatentWatch.com. Retrieved from https://www.drugpatentwatch.com/drug/ozempic